Home » Stocks » SESN

Sesen Bio, Inc. (SESN)

Stock Price: $1.62 USD -0.04 (-2.41%)
Updated Jan 22, 2021 12:55 PM EST - Market open
Market Cap 210.75M
Revenue (ttm) 11.24M
Net Income (ttm) -48.10M
Shares Out 117.89M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.62
Previous Close $1.66
Change ($) -0.04
Change (%) -2.41%
Day's Open 1.65
Day's Range 1.60 - 1.69
Day's Volume 1,349,164
52-Week Range 0.39 - 1.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today repo...

Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Zacks Investment Research - 1 month ago

Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma ...

Seeking Alpha - 2 months ago

Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today repo...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today annou...

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Zacks Investment Research - 4 months ago

Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today repo...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 5, 2020 – Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with c...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu P...

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today anno...

Seeking Alpha - 8 months ago

Sesen Bio, Inc. (SESN) CEO Dr.

Seeking Alpha - 10 months ago

Sesen Bio's (SESN) CEO Thomas Cannell on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Sesen Bio: Growing A Position Through The Rolling BLA Summary

Seeking Alpha - 11 months ago

Sesen Bio With High Probability FDA Approval Upcoming

Seeking Alpha - 1 year ago

Sesen Bio's (SESN) CEO Thomas Cannell on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ENZN trades at all time highs, adjusted for dividends, and double the "base case" of the liquidation value.

Other stocks mentioned: ENZN
Seeking Alpha - 1 year ago

The company reported a positive data update from the Phase 3 VISTA trial for BCG refractory high-grade NMIBC patients.

Seeking Alpha - 1 year ago

Sesen plunged 35% after announcing a stock offering.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

The stock more than doubled within the past two months.

Zacks Investment Research - 1 year ago

Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.

Seeking Alpha - 1 year ago

The company meets with the FDA on May 20 to discuss manufacturing aspects.

Seeking Alpha - 1 year ago

Sesen Bio, Inc. (SESN) CEO Thomas Cannell on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

An upcoming data readout for the phase 3 VISTA trial using Vicinium in NMIBC patients who don't respond to BCG therapy is expected by May 13, 2019.

Seeking Alpha - 1 year ago

On March 4, Sesen Bio's President and CEO Dr. Thomas Cannell held a conference call, primarily to update the status and progress of Vicinium.

About SESN

Sesen Bio, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also d... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2014
CEO
Thomas Cannell
Employees
25
Stock Exchange
NASDAQ
Ticker Symbol
SESN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Sesen Bio stock is "Strong Buy." The 12-month stock price forecast is 3.42, which is an increase of 111.11% from the latest price.

Price Target
$3.42
(111.11% upside)
Analyst Consensus: Strong Buy